Table 4. Clinical characteristics of the 163 patients followed up for at least 3 years, compared according to whether or not they experienced recurrence.

Characteristic	Total (n=163)	3-y recurrence (n=62)	No 3-y recurrence (n=101)	P
Age (y)	59.9±10.2	62.3±9.8	58.4±10.2	0.019
Age ≥60 years	87 (53.4)	43 (69.4)	44 (43.6)	0.001
Female	115 (70.6)	40 (64.5)	75 (74.3)	0.185
BMI (kg/m2)	20.7±2.4	20.7±2.2	20.6±2.6	0.798
Current or past smoker	29 (17.8)	10 (16.1)	19 (18.8)	0.664
Previous history of TB treatment	56 (34.4)	24 (38.7)	32 (31.7)	0.359
Previous history of NTM treatment	8 (4.9)	7 (11.3)	1 (1.0)	0.005
Comorbidity
COPD	20 (12.3)	7 (11.3)	13 (12.9)	0.765
Diabetes mellitus	15 (9.2)	6 (9.7)	9 (8.9)	0.869
Chronic liver disease	13 (8.0)	5 (8.1)	8 (7.9)	>0.999
Malignancy	33 (20.2)	13 (21.0)	20 (19.8)	0.857
Etiology				0.701
Mycobacterium avium	82 (50.3)	30 (48.4)	52 (51.5)
Mycobacterium intracellulare	81 (49.7)	32 (51.6)	49 (48.5)
Positive AFB smear at treatment initiation	45 (27.6)	19 (30.6)	26 (25.7)	0.497
Number of involved lobes	3.4±1.3	3.7±1.4	3.3±1.2	0.043
Use of injectable aminoglycosides	58 (35.6)	19 (30.6)	39 (38.6)	0.302
Daily therapy	163 (100.0)	62 (100.0)	101 (100.0)	–
Surgical resection	4 (2.5)	3 (4.8)	1 (1.0)	0.154
Shorter treatment duration (9–11 months)	43 (26.4)	18 (29.0)	25 (24.8)	0.547
Time to initiate treatment after diagnosis (months)	4.2 (1.6–10.7)	4.1 (1.1–11.8)	4.3 (1.8–10.4)	0.783
Follow-up duration after treatment completion (months)	68.5 (52.4–89.6)	67.6 (52.5–83.7)	69.1 (51.5–90.7)	0.828

BMI, body mass index; TB, tuberculosis; NTM, nontuberculous mycobacteria; COPD, chronic obstructive lung disease; AFB, acid-fast bacilli. Data are presented as mean (± standard deviation), median (interquartile range), or number (%).